Nefrosol Cu Potasiu (Sodium Hydrogen Carbonate, Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Calc)

The active ingredients provide a balanced mix of electrolytes that directly enter the bloodstream when infused. These ions help re‑establish normal extracellular fluid volume, correct osmotic imbalances, support nerve and muscle function, and maintain acid‑base homeostasis through bicarbonate buffering, thereby addressing the physiological deficits caused by fluid loss.

The dose of Nefrosol Cu Potasiu is individualized by the prescribing clinician based on the patient’s electrolyte status, fluid requirements, weight, renal function and the clinical scenario. Healthcare professionals calculate the appropriate volume and rate of infusion to safely correct the identified deficits.

Safety data for Nefrosol Cu Potasiu in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it must be prescribed and monitored by a qualified healthcare provider.

To order Nefrosol Cu Potasiu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Nefrosol Cu Potasiu offers a comprehensive electrolyte profile that includes sodium, potassium, magnesium, calcium and bicarbonate, making it suitable for a broad range of fluid‑replacement needs. Compared with simpler saline solutions, it provides additional ions that help correct more complex electrolyte disturbances without the need for multiple separate infusions.

The product must be stored at 2‑8 °C, kept refrigerated, protected from light, and should never be frozen or shaken. Before use, inspect the container for any signs of contamination or damage, and allow the solution to reach room temperature if required by the administration protocol.

Nefrosol Cu Potasiu is administered intravenously as a sterile solution for injection. The infusion rate is determined by the prescribing clinician, taking into account the patient’s electrolyte deficits, cardiac status and renal function. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy monitoring.

Serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, anaphylactic reactions, fluid overload leading to pulmonary edema, and profound metabolic alkalosis. Continuous monitoring of electrolyte levels, cardiac rhythm and fluid balance is essential to mitigate these risks.

Patients with known hypersensitivity to any component of the solution, those with uncontrolled hyperkalemia, severe renal failure not managed with dialysis, or individuals at high risk for fluid overload should not receive Nefrosol Cu Potasiu unless a clinician determines that benefits outweigh the risks.